The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People
Mayo Clinic
60 participants
Oct 3, 2025
INTERVENTIONAL
Conditions
Summary
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. There is evidence that α-cell proglucagon processing is subject to paracrine regulation by the β-cell3. It is unclear if the effects of GLP1R agonism on islet GLP-1 differ in Type 1 diabetes (T1DM) compared to T2DM. This experiment will examine the effect of glycemic control ± a GLP1R agonist on islet GLP-1 in people with (T2DM) and without (T1DM) β-cells.
Eligibility
Inclusion Criteria1
- Type 1 or type 2 diabetes treated with insulin
Exclusion Criteria7
- Age \< 25 or \> 70 years.
- HbA1c \> 10.0%
- For female subjects: positive pregnancy test at the time of enrollment or study
- History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
- Prior use of GLP-1 receptor agonists in the previous year.
- Active systemic illness or malignancy.
- Symptomatic macrovascular or microvascular disease.
Interventions
Liraglutide 0.6mg
Saline in syringes to serve as placebo for single blind study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06976619